Bionovo, a pharmaceutical company focusing on women’s health and cancer, has named David Boyle senior vice president and chief financial officer.

Boyle comes to Bionovo with extensive operational and international financial experience, which includes similar titles at AVI BioPharma and XOMA.

"Beyond his extensive background in finance, David brings to Bionovo expertise in several business and operational areas," said Isaac Cohen, Bionovo's chairman and chief executive officer.  "We are excited to have David join our management team here at Bionovo as we move forward the phase III clinical development of Menerba, our drug candidate for the treatment of menopausal hot flashes.”